When MAT2A is blocked in MTAP-deleted cancer cells, some cells switch to using other pathways—like polyamine synthesis—to make the molecules they need, which may allow them to survive the treatment.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether polyamine pathway upregulation is a common resistance mechanism to MAT2A inhibitors across clinical trials.
A systematic review and meta-analysis of all published clinical and preclinical studies reporting metabolic changes in MTAP-deleted tumors after MAT2A inhibitor exposure, focusing on polyamine synthesis enzymes and correlating with treatment resistance.
Whether combining MAT2A and polyamine synthesis inhibitors prevents resistance in MTAP-deleted tumors.
A double-blind RCT of 180 patients with MTAP-deleted tumors randomized to IDE397 alone vs. IDE397 + polyamine synthesis inhibitor (e.g., DFMO), with primary endpoint of time to progression and secondary endpoints of polyamine metabolite levels and resistance biomarkers.
Whether upregulation of polyamine synthesis correlates with acquired resistance to IDE397 in patients.
A prospective cohort of 100 patients with MTAP-deleted tumors treated with IDE397, collecting serial tumor biopsies at baseline, 4 weeks, and progression to measure polyamine pathway gene expression and metabolite levels.
Whether resistant tumors have higher baseline polyamine pathway activity than sensitive tumors.
A matched case-control study comparing 40 patients with acquired resistance to IDE397 with 40 matched responders, analyzing pre-treatment tumor tissue for polyamine enzyme expression and metabolite levels.
The baseline expression of polyamine synthesis enzymes in MTAP-deleted tumors across tumor types.
A cross-sectional analysis of 300 MTAP-deleted tumor samples measuring mRNA and protein levels of key polyamine enzymes (ODC1, SRM, SMS) and correlating with tumor origin and grade.